Adinazolam
 | |
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic |
| Elimination half-life | < 3 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C19H18ClN5 |
| Molar mass | 351.8 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
|
WikiDoc Resources for Adinazolam |
|
Articles |
|---|
|
Most recent articles on Adinazolam |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Adinazolam at Clinical Trials.gov Clinical Trials on Adinazolam at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Adinazolam
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Adinazolam Discussion groups on Adinazolam Patient Handouts on Adinazolam Directions to Hospitals Treating Adinazolam Risk calculators and risk factors for Adinazolam
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Adinazolam |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Adinazolam[1] (marketed under the brand name Deracyn) is a benzodiazepine derivative, and more specifically, a triazolobenzodiazepine (TBZD). It possesses anxiolytic, anticonvulsant, sedative, and antidepressant[2] properties. Adinazolam was developed by Dr. Jackson B. Hester, who was seeking to enhance the antidepressant properties of alprazolam, which he also developed.[3] Adinazolam was never FDA approved and never made available to the public market.
Indications
Adinazolam is indicated as a treatment for depression and anxiety.
Pharmacodynamics and pharmacokinetics
Adinazolam binds to peripheral-type benzodiazepine receptors that interact allosterically with GABA receptors as an agonist to produce inhibitory effects.
Metabolism
Adinazolam was reported to have active metabolites in the August 1984 issue of The Journal of Pharmacy and Pharmacology.[4] The main metabolite is N-desmethyladinazolam.[5] NDMAD has an approximately 25-fold high affinity for benzodiazepine receptors as compared to its precursor, accounting for the benzodiazepine-like effects after oral administration. (REF1) Multiple N-dealkylations lead to the removal dimethyl-aminoethyl side chain, leading to the difference in its potency. (REF5) The other two metabolites are alpha-hydroxyalprazolam and estazolam.[6] In the August 1986 issue of that same journal, Sethy, Francis and Day reported that proadifen inhibited the formation of N-desmethyladinazolam.[7]
See also
References
- ↑ FR Patent 2248050
- ↑ Lahti, Robert A.; Vimala H. Sethy; Craig Barsuhn; Jackson B. Hester (November 1983). "Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine". Neuropharmacology. 22 (11): 1277–82. doi:10.1016/0028-3908(83)90200-9. PMID 6320036.
- ↑ "Discovers Award 2004" (PDF). Special Publications. Pharmaceutical Research and Manufacturers of America. April 2004. p. 39. Archived from the original (PDF) on August 24, 2006. Retrieved August 18, 2006.
- ↑ Sethy, Vimala H.; R. J. Collins; E. G. Daniels (August 1984). "Determination of biological activity of adinazolam and its metabolites". Journal of Pharmacy and Pharmacology. 36 (8): 546–8. doi:10.1111/j.2042-7158.1984.tb04449.x. PMID 6148400.
- ↑ Peng, G. W. (August 1984). "Assay of adinazolam in plasma by liquid chromatography". Journal of Pharmaceutical Sciences. 73 (8): 1173–5. doi:10.1002/jps.2600730840. PMID 6491930.
- ↑ Fraser, A. D.; A. F. Isner; W. Bryan (November–December 1993). "Urinary screening for adinazolam and its major metabolites by the Emit d.a.u. and FPIA benzodiazepine assays with confirmation by HPLC". Journal of Analytical Toxicology. 17 (7): 427–31. doi:10.1093/jat/17.7.427. PMID 8309217.
- ↑ Sethy, Vimala H.; Jonathan W. Francis; J. S. Day (August 1986). "The effect of proadifen on the metabolism of adinazolam". Journal of Pharmacy and Pharmacology. 38 (8): 631–2. doi:10.1111/j.2042-7158.1986.tb03099.x. PMID 2876087.